Is “Big Three Positive” Hepatitis B with Fatty Liver Severe?

May 18, 2022 Source: Cainiu Health
Dr. Zhao Haiming
Introduction
If a patient has both “Big Three Positive” (i.e., hepatitis B surface antigen [HBsAg], hepatitis B e antigen [HBeAg], and hepatitis B core antibody [anti-HBc] all positive) and fatty liver disease, hepatic protection and liver health maintenance are essential. The coexistence of these two liver conditions does not necessarily indicate severe disease; severity should be assessed comprehensively based on the patient’s clinical symptoms and relevant diagnostic tests. “Big Three Positive” is a serological pattern indicative of chronic hepatitis B infection. Fatty liver disease primarily results from disturbances in intrahepatic lipid metabolism.

In daily life, some individuals with “Big Three Positive” (a term referring to chronic hepatitis B virus infection characterized by positive HBsAg, HBeAg, and anti-HBc) combined with moderate-to-severe fatty liver disease experience significant impacts on their quality of life. “Big Three Positive” fatty liver is a subtype of fatty liver disease and represents a common clinical condition. So, how serious is “Big Three Positive” fatty liver?

How serious is “Big Three Positive” fatty liver?

When “Big Three Positive” hepatitis B and fatty liver coexist, patients must prioritize liver protection and support healthy liver function. The concurrent presence of these two liver conditions does not automatically indicate severe disease; rather, severity should be assessed comprehensively based on clinical symptoms and relevant diagnostic tests. “Big Three Positive” refers to a specific phase of chronic hepatitis B infection, whereas fatty liver primarily results from disturbances in intrahepatic lipid metabolism. Both are relatively common liver disorders and frequently occur together. If symptoms are pronounced and liver function tests reveal markedly abnormal results—e.g., serum transaminase levels elevated more than tenfold above the upper limit of normal—this suggests a relatively severe disease state. Conversely, mild transaminase elevation without accompanying clinical symptoms generally indicates milder disease.

Patients with “Big Three Positive” hepatitis B require regular hospital follow-ups. Physicians adjust treatment plans dynamically based on periodic test results. With favorable prognosis and appropriate management, this condition typically poses minimal risk. However, failure to address underlying liver pathology may lead to complications—including hepatocellular carcinoma. Therefore, patients with “Big Three Positive” hepatitis B should take their condition seriously: ensure adequate rest, adhere strictly to scheduled medical check-ups, and correctly use antiviral medications as prescribed. Proactive, evidence-based treatment helps prevent complications associated with chronic hepatitis B.

In daily life, everyone should pay close attention to personal health maintenance, strengthen their resistance and immune function, and seek timely medical evaluation and treatment upon noticing any abnormalities. We hope this information proves helpful to you!